Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.

ABSTRACT: Prostate cancer (PCa) is one of the most frequently diagnosed cancer among men in the western societies. Many PCa patients bear tumors that will not threat their lives if left untreated or if treatment is delayed. Our inability for early identification of these patients has resulted in massive overtreatment. Therefore, there is a great need of finding biomarkers for patient stratification according to prognostic risk; as well as there is a need for novel targets that can allow the development of effective treatments for patients that progress to castration-resistant PCa. Most biomarkers in cancer are proteins, including the widely-used prostate-specific antigen (PSA). Recent developments in mass spectrometry allow the identification and quantification of thousands of proteins and posttrans

SUBMITTER: Flores-Morales A 

PROVIDER: S-EPMC5674010 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature